FOLH1 and prostate cancer: Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer (PCa) including metastatic castrate-resistant prostate cancer (mCRPC) and has emerged both as a promising imaging marker and as a therapeutic target [1, 2].